Connect with us
Information

Australia
North America
World

Investing News NetworkYour trusted source for investing success

North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

cynata therapeutics

POPULAR ARTICLES

NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus MSCs in Patients with Osteoarthritis

Genetics Outlook 2019: CRISPR Technology Advances

Genetics Outlook 2019: CRISPR Technology Advances

Pharmaceutical Investing

Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD

LATEST ARTICLES

Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Genetics Investing

Cynata Therapeutics Receives Orphan Drug Designation from FDA

FDA Grants Orphan Drug Designation to Cynata’s Lead Cymerus MSC Product, CYP-001

Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial

Treatment Commences in Second Patient Cohort in Cynata’s World First Clinical Trial

Longevity Investing

Cynata Executes MoU for Commercial Evaluation with Celularity

Biotech Investing

What Is Regenerative Medicine?

Genetics Investing

Genetics Outlook 2017: The Revolution Nears

Biotech Investing

Top Trends for Genetics Stocks in 2017

Biotech Investing

Is the Stem Cell Market Heating Up? Acquisition Activity Suggests Yes.

How 3 Top Stem Cell Research Companies Are Changing Biotech Investing

How 3 Top Stem Cell Research Companies Are Changing Biotech Investing

Latest News

Trigg Expands Tier-1 Australian Antimony-Gold Tenure with Grades up to 61% Sb & 1045 g/t Au

Presentation to Food and Ingredients China 2025 Conference

Ulytau Project Exploration Licence Granted

Alvopetro Announces Year End 2024 Financial Results, Q1 2025 Dividend of US$0.10/share and Filing of our AIF

Independent Survey Confirms Public Support for Falco Horne 5 Project